Astatine-211 is one of the most promising alpha emitters in targeted alpha therapy - a half-life of ~7.2 hours long enough for radiolabeling and delivery, short enough to limit patient radiation burden, and a production route that, until recently, only a handful of cyclotrons worldwide could support.

This Comecer scientific webinar follows At-211 from cyclotron to clinic. Mario Malinconico, Scientific Leader at Comecer, opens with the market landscape for targeted alpha therapy, why At-211's decay properties make it such a strong candidate, and the production technology, behind bringing it to the clinic.

Guest speaker Sherry Yonnello, Professor and Cyclotron Institute Director at Texas A&M University & Federica Pianeschi, Associate Professor at UTHealth Houston, then share their own experience with At-211, including a look inside their lab and the equipment behind their work.

Continue the Scientific Webinar Series

Join us on December 15 for the next session:

Register now